Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
3.880
+0.020 (0.52%)
At close: Jul 25, 2025, 4:00 PM
3.820
-0.060 (-1.55%)
After-hours: Jul 25, 2025, 7:56 PM EDT

Company Description

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.

The company’s clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases.

It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.

The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Alumis Inc.
Alumis logo
CountryUnited States
Founded2021
IPO DateJun 28, 2024
IndustryBiotechnology
SectorHealthcare
Employees170
CEOMartin Babler

Contact Details

Address:
280 East Grand Avenue
South San Francisco, California 94080
United States
Phone650 231 6625
Websitealumis.com

Stock Details

Ticker SymbolALMS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$16.00
CIK Code0001847367
CUSIP Number022307102
ISIN NumberUS0223071020
SIC Code2834

Key Executives

NamePosition
Martin Babler Ph.D.President, Chief Executive Officer and Chairman
Dr. David M. Goldstein Ph.D.Chief Scientific Officer
Roy C. Hardiman J.D.Chief Business and Strategy Officer
John R. Schroer C.F.A.Chief Financial Officer
Sanam Pangali J.D.Chief Legal Officer and Corporate Secretary
Derrick RichardsonSenior Vice President of People and Culture
Claire Langrish Ph.D.Senior Vice President and Head of Immunology and Translational Science
Philip Nunn Ph.D.Senior Vice President of Pharmacology and Project Team Leader
Dr. Jorn Drappa M.D., Ph.D.Chief Medical Officer and Head of Research and Development
Mark BradleyChief Development Officer

Latest SEC Filings

DateTypeTitle
Jul 3, 2025S-3Registration statement under Securities Act of 1933
Jun 30, 20258-K/A[Amend] Current report
Jun 16, 2025ARSFiling
Jun 16, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 16, 2025DEF 14AOther definitive proxy statements
Jun 10, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 10, 2025SCHEDULE 13D/AFiling
May 23, 2025SCHEDULE 13D/AFiling
May 23, 2025SCHEDULE 13D/AFiling
May 21, 20258-KCurrent Report